secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001714899-24-000076
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali reports Q4 net loss $119.5M, announces ~$500M PIPE and spin-out of preclinical small molecules
--------------------------------------------------------------------------------

- Net loss $119.5M in Q4 vs $98.7M YoY; full year net loss $145.2M vs $326.0M on $330.5M collaboration revenue (Biogen ATV:Abeta option $293.9M).
- PIPE financing of ~$500M gross proceeds: 3.24M shares and 26.05M pre-funded warrants at ~$17.07 per unit; cash runway into 2028.
- Plans to spin out preclinical small molecule portfolio to focus on TV-enabled platforms; CD98hc TV platform announced.
- Phase 2/3 COMPASS (MPS II) and HEALEY ALS (DNL343) enrollment expected to complete in 2024.
- SAR443820/DNL788 (RIPK1) missed ALS Phase 2 HIMALAYA primary endpoint; ongoing MS Phase 2 unaffected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000076/0001714899-24-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489924000076/dnli-20240227.htm
  HTML page:      https://secwatch.observer/filing/0001714899-24-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer